Products, Major Customers and Concentrations of Credit Risks

Our primary product groups are infusion therapy, critical care and oncology. In prior periods, we included Tego needlefree hemodialysis connector and Lopez enteral valve under "other". The Tego is now included under Infusion Therapy. The Lopez Valve is now included under Critical Care. Other reclassifications were done for certain items in the market segments in the prior periods. Prior year amounts have been adjusted to conform to the current presentation. The breakdown by market segment for the years ended December 31, 2014, 2013 and 2012 are as follows:



	2014		2013		2012
Infusion therapy	$	215,982	$	220,982	$	226,092
Critical care	55,074		54,326		58,926
Oncology	36,949		37,075		29,957
Other	1,255		1,333		1,894
	$	309,260	$	313,716	$	316,869

We sell products worldwide, on credit terms on an unsecured basis, to medical product manufacturers, independent medical supply distributors, and directly to the end customer. The manufacturers and distributors, in turn, sell our products to healthcare providers. For the years ended December 31, 2014, 2013 and 2012, we had worldwide sales to one manufacturer, Hospira, of 36%, 39% and 42%, respectively, of consolidated revenue. As of December 31, 2014, and 2013, we had accounts receivable from Hospira of 27% and 32%, respectively, of consolidated accounts receivable.

Domestic sales accounted for 69%, 71% and 75% of total revenue in 2014, 2013 and 2012, respectively. International sales, which are determined by the destination of the product shipment, accounted for 31%, 29% and 25% of total revenue in 2014, 2013 and 2012, respectively.

The table below presents our gross long-lived assets by country:



	As of December 31,
	2014		2013
Mexico	$	51,554	49,454
Slovakia	16,643		18,422
Italy	4,855		5,428
Germany	638		547
Total foreign	$	73,690	$	73,851
United States	151,024		139,150
Worldwide total	$	224,714	$	213,001